PATENT CLAIM ANALYSIS

Application Number: 16165662
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-02
Patent Classification: ["514", "333000"]

Abstract:
The invention discloses compounds of Formula I, wherein X 1 , X 2 , R 1 , and R 2  are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.

Claim (Index 11):
The pharmaceutical composition of  claim 10 , wherein the potentiator is selected from the group consisting of Ivacaftor (VX-770), CTP-656, NVS-QBW251 FD1860293, PTI-808, N-(3-carbamoyl-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-2-yl)-1H-pyrazole-5-carboxamide, and 3-amino-N-[(2S)-2-hydroxypropyl]-5-{[4-(trifluoromethoxy)phenyl]sulfonyl}pyridine-2-carboxamide.

Metadata:
- Claim Count in Document: 7.0
- Percentile: 97.0
- Lexical Diversity: 1.63415
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15843917', '15205512', '15496094', '14925649', '15164317']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8230815064922216
- 35 USC 102 Novelty (BERT): 0.5930383072167764
- Combined Prediction Score: 0.8000771865646771
- Mean Citation Score: 427.462666
- Max Citation Score: 563.3792
- Similarity Product: 406.5903056655884

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test